Viatris Inc. Secures FDA Nod for Generic Symbicort Equivalent, Breyna
US-based Viatris Inc., (NASDAQ: VTRS) has announced that the US Food and Drug Administration (FDA)...
Viatris
Viatris Reports Q4 2022 Results, Highlights China Growth
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...
NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China
The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...
Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review
The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...